Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Either RAC exam (Devices and Drugs) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 05 November 2015 | By Michael Mezher
After reviewing the safety profile of human papillomavirus (HPV) vaccines, a European Medicines Agency's (EMA) committee found no evidence the vaccines cause two rare conditions in young women, concluding that "there is no reason to change the way the vaccines are used."
There are currently three centrally-authorized HPV vaccines in the EU – Gardasil/Silgard, Gardasil 9 and Cervarix – to protect against cervical cancer and other HPV related conditions.
Upon initiating its review, EMA stated its goal was to "clarify aspects of [the vaccines'] safety profile," and said the review did not question whether "the benefits of HPV vaccines outweigh their risks."
To conduct the review, PRAC consulted with "leading experts in the field" and "thoroughly reviewed the published research, data from clinical trials and reports of suspected side effects from patients and healthcare professionals, as well as data supplied by Member States."
PRAC estimates that approximately 150 per million girls and young women develop CRPS and POTS each year, but "found no evidence that the overall rates of [CRPS and POTS] in vaccinated girls were different from expected rates," even when factoring for underreporting.
The committee also acknowledged that more than 80 million girls and women worldwide have received HPV vaccines and the vaccine "is expected to prevent many cases of cervical cancer … which is responsible for tens of thousands of deaths in Europe each year."
PRAC is recommending there be no changes to how the vaccine is used, and finds no reason to change the product information.
In July, Danish health authorities requested EMA look into the safety of HPV vaccines after adverse event reports claimed the vaccine had caused complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in some patients.
Between 2009, when Denmark implemented a vaccination program and June 2015, Denmark received 1,305 adverse event reports related HPV vaccines. During the same period, health authorities in Denmark reported more than 1.6 million doses of the vaccine were sold.
However, according to Danish authorities, only 47 reports of CRPS (as of 30 September 2014) and 66 reports of POTS (as of 31 December 2014) have been made globally.
EMA
Tags: Pharmacovigilance Risk Assessment Committee, PRAC, HPV vaccine, Gardasil, Cervarix, POTS, CRPS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.